NASDAQ:ABSI Absci (ABSI) Stock Price, News & Analysis $2.67 -0.07 (-2.55%) Closing price 04:00 PM EasternExtended Trading$2.70 +0.03 (+1.12%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Absci Stock (NASDAQ:ABSI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Absci alerts:Sign Up Key Stats Today's Range$2.59▼$2.7250-Day Range$2.23▼$3.2252-Week Range$2.01▼$6.33Volume2.13 million shsAverage Volume2.74 million shsMarket Capitalization$340.58 millionP/E RatioN/ADividend YieldN/APrice Target$8.40Consensus RatingBuy Company OverviewAbsci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.Read More… Absci Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreABSI MarketRank™: Absci scored higher than 40% of companies evaluated by MarketBeat, and ranked 710th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAbsci has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAbsci has only been the subject of 4 research reports in the past 90 days.Read more about Absci's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Absci are expected to grow in the coming year, from ($0.89) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Absci is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Absci is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbsci has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Absci's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.56% of the float of Absci has been sold short.Short Interest Ratio / Days to CoverAbsci has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Absci has recently increased by 3.95%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbsci does not currently pay a dividend.Dividend GrowthAbsci does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted20.56% of the float of Absci has been sold short.Short Interest Ratio / Days to CoverAbsci has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Absci has recently increased by 3.95%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment0.98 News SentimentAbsci has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Absci this week, compared to 3 articles on an average week.Search Interest17 people have searched for ABSI on MarketBeat in the last 30 days. This is an increase of 183% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Absci to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Absci insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.81% of the stock of Absci is held by insiders.Percentage Held by Institutions52.05% of the stock of Absci is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Absci's insider trading history. Receive ABSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Absci and its competitors with MarketBeat's FREE daily newsletter. Email Address ABSI Stock News HeadlinesAnalysts Set Absci Co. (NASDAQ:ABSI) Price Target at $8.40May 25, 2025 | americanbankingnews.comAbsci (NASDAQ:ABSI) Upgraded at Wall Street ZenMay 24, 2025 | americanbankingnews.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. May 30, 2025 | Porter & Company (Ad)Assessing Absci: Insights From 6 Financial AnalystsMay 17, 2025 | nasdaq.comEarnings call transcript: Absci Q1 2025 sees stock surge post-earningsMay 15, 2025 | investing.comAbsci Corporation (ABSI) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comAbsci Reports Business Updates and First Quarter 2025 Financial and Operating ResultsMay 13, 2025 | globenewswire.comAbsci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel DiseaseMay 13, 2025 | globenewswire.comSee More Headlines ABSI Stock Analysis - Frequently Asked Questions How have ABSI shares performed this year? Absci's stock was trading at $2.62 at the beginning of the year. Since then, ABSI stock has increased by 0.2% and is now trading at $2.6250. View the best growth stocks for 2025 here. How were Absci's earnings last quarter? Absci Co. (NASDAQ:ABSI) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.02. The company earned $1.18 million during the quarter, compared to analysts' expectations of $1.07 million. Absci had a negative net margin of 2,321.56% and a negative trailing twelve-month return on equity of 46.56%. Read the conference call transcript. When did Absci IPO? Absci (ABSI) raised $200 million in an initial public offering (IPO) on Thursday, July 22nd 2021. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. Who are Absci's major shareholders? Absci's top institutional shareholders include ARK Investment Management LLC (8.59%), Fred Alger Management LLC (3.37%), Massachusetts Financial Services Co. MA (1.81%) and Sumitomo Mitsui Trust Group Inc. (1.17%). Insiders that own company stock include Phoenix Venture Partners Ii Lp, Redmile Group, Llc and Zachariah Jonasson. View institutional ownership trends. How do I buy shares of Absci? Shares of ABSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Absci own? Based on aggregate information from My MarketBeat watchlists, some other companies that Absci investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Arista Networks (ANET) and CrowdStrike (CRWD). Company Calendar Last Earnings5/13/2025Today5/30/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNASDAQ:ABSI CIK1672688 Webwww.absci.com Phone360-949-1041FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$8.40 High Stock Price Target$10.00 Low Stock Price Target$7.00 Potential Upside/Downside+212.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$110.57 million Net Margins-2,321.56% Pretax Margin-2,319.25% Return on Equity-46.56% Return on Assets-39.74% Debt Debt-to-Equity Ratio0.01 Current Ratio5.63 Quick Ratio5.63 Sales & Book Value Annual Sales$4.82 million Price / Sales71.16 Cash FlowN/A Price / Cash FlowN/A Book Value$1.90 per share Price / Book1.41Miscellaneous Outstanding Shares127,559,000Free Float103,589,000Market Cap$342.62 million OptionableOptionable Beta2.19 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ABSI) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Absci Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Absci With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.